您当前的位置：

KY19382

(Synonyms: A3051)

目录号: PL11759 纯度: ≥98%

KY19382 是一种有效的和具有口服活性的 CXXC5-DVL 和 GSK3β 的双重抑制剂，IC50 值分别为 19 和 10 nM。KY19382 通过对 CXXC5-DVL 相互作用和 GSK3β 活性的抑制作用激活 Wnt/β-catenin 信号传导。KY19382 可用于高脂饮食 (HFD) 诱发的代谢性疾病的研究。

CAS No. :2226664-93-1

商品编号	规格	价格	会员价
PL11759-5mg	5mg	¥1975.00	请登录
PL11759-10mg	10mg	¥3575.00	请登录
PL11759-25mg	25mg	¥5775.00	请登录
PL11759-50mg	50mg	¥7905.00	请登录
PL11759-100mg	100mg	¥10795.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	KY19382
英文名称	KY19382
英文别名	KY19382;5,6-Dichloro-3-[(3Z)-3-methoxyiminoindol-2-yl]-1H-indol-2-ol;A3051
Cas No.	2226664-93-1
分子式	C₁₇H₁₁Cl₂N₃O₂
分子量	360.19
包装储存	Powder -20°C 3 years；4°C 2 years
详情描述	KY19382 是一种有效的和具有口服活性的 CXXC5-DVL 和 GSK3β 的双重抑制剂，IC50 值分别为 19 和 10 nM。KY19382 通过对 CXXC5-DVL 相互作用和 GSK3β 活性的抑制作用激活 Wnt/β-catenin 信号传导。KY19382 可用于高脂饮食 (HFD) 诱发的代谢性疾病的研究。

产品详情	KY19382 是一种有效的和具有口服活性的 CXXC5-DVL 和 GSK3β 的双重抑制剂，IC₅₀ 值分别为 19 和 10 nM。KY19382 通过对 CXXC5-DVL 相互作用和 GSK3β 活性的抑制作用激活 Wnt/β-catenin 信号传导。KY19382 可用于高脂饮食 (HFD) 诱发的代谢性疾病的研究。
生物活性	KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC 50 s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be used for the research of high fat diet (HFD) induced metabolic diseases.
性状	Solid
IC50 & Target[1][2]	CXXC5-DVL 19 nM (IC50) GSK3β 10 nM (IC
体外研究(In Vitro)	KY19382 (0.01 and 0.1 μM; 48 h) promotes ATDC5 cells proliferation. KY19382 (0.1 μM; 3 d) up-regulates the mRNA levels of chondrogenic differentiation markers in ATDC5 and C28/I2 cells. KY19382 (0.01 and 0.1 μM; 24 h) inactivates GSK3α/β in ATDC5 cells. KY19382 (0.1 μM; 4 h) interrupts the CXXC5-DVL interaction in ATDC5 cells. KY19382 (0.001-10 μM; 18 h) enhances the TOPFlash activity in HEK293 reporter cells. KY19382 (0.1 μM; 48 h) elevates nuclear translocation of β-catenin in ATDC5 cells. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	KY19382 (0.1 mg/kg; i.p. once daily for 2 weeks) delays growth plate senescence in older mice and promotes growth plate maturation in rapidly growing young mice. KY19382 (0.1 mg/kg; i.p. once daily for 10 weeks) significantly increases the length of tibiae in mice. KY19382 (5 mg/kg; i.p.) displays a relatively favorable bioavailability (F=16.74%), showing half-life of 16.20 h and an exposure level of 6,555.79 ng?h/ml. KY19382 (A3051) (25 mg/kg; p.o. once daily for 16 weeks) shows reduction in adipocyte size and anti-inflammatory effects. A3051 (25 mg/kg; p.o. once daily for 5 days) reduces fasting glucose in mice. A3051 (25 mg/kg; p.o. once daily for 3 weeks) reduces the hepatosteatosis in mice. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Choi S, et, al. CXXC5 mediates growth plate senescence and is a target for enhancement of longitudinal bone growth. Life Sci Alliance. 2019 Apr 10; 2(2): e201800254. [2]. Choi KY, et, al. Compositions and methods for suppressing and/or treating metabolic diseases and/or a clinical condition thereof. WO2020079569.

溶解度数据	In Vitro: DMSO : 5 mg/mL (13.88 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. Choi S, et, al. CXXC5 mediates growth plate senescence and is a target for enhancement of longitudinal bone growth. Life Sci Alliance. 2019 Apr 10; 2(2): e201800254.
[2]. Choi KY, et, al. Compositions and methods for suppressing and/or treating metabolic diseases and/or a clinical condition thereof. WO2020079569.

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

KY19382

相关产品

The molarity calculator equation

The dilution calculator equation